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Abstract
This work is the first attempt to quantify the overall effects of a 13-valent pneumococcal conjugate vaccine (PCV13)
vaccination programme in the Dutch population taking into account all the direct and indirect effects of the vaccine on
invasive pneumococcal disease. Using available Dutch data, a dynamic transmission model for the spread of pneumococci
and potential subsequent invasive pneumococcal disease has been adapted to the Dutch setting. Overall, invasive
pneumococcal disease cases in the Netherlands are predicted to decrease from a pre-vaccination level of 2623 cases
annually to 2475, 2289, 2185, 2179, and 2178 cases annually 5-, 10-, 20-, 30-, and 40-years, respectively, post-vaccination.
Therefore, vaccination with PCV13 in the Netherlands is predicted to lower invasive pneumococcal disease cases per year by
up to 445 cases in the medium- to long-term. The results are quite robust for the sensitivity analyses performed on the
parameters that regulate herd immunity and competition between vaccine and non-vaccine types.
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Introduction
Streptococcus pneumoniae (pneumococcus) is the main cause of
pneumonia, acute otitis media, bloodstream infections (bacterae-
mia) and severe forms of meningitis [1]. The burden of disease
related to the bacterium S. pneumoniae is highly relevant from a
public health perspective [2–4]. In nature, .90 immunologically
different pneumococcal serotypes have been identified, which
differ in the chemical compositions of their polysaccharide
capsules. Each serotype behaves differently in respect to several
properties, including invasiveness, affinity towards age groups,
disease manifestation, carriage, and outbreaks. Preventing pneu-
mococcal disease caused by specific serotypes is possible through
vaccination.
The 7-valent pneumococcal conjugate vaccine (PCV7), which
became available in 2000, contains serotypes 4, 6B, 9V, 14, 18C,
19F, and 23F. The 10-valent (PCV10) and 13-valent (PCV13)
pneumococcal conjugate vaccines (PCVs) subsequently became
available in 2009 and 2010, respectively. PCV10 includes the
serotypes contained in PCV7 and three additional serotypes:
serotypes 1, 5, and 7A. PCV13 contains the serotypes of PCV10
and another three additional serotypes: serotypes 3, 6A, and 19A.
Conjugated vaccines administered to paediatric populations have
provided direct protection in many settings [5,6].
An additional benefit of PCV7 and PCV13 paediatric programs
has been the reduction of pneumococcal disease in unvaccinated
cohorts due to herd protective effects [7–13]. Among vaccinated
children, reduction of nasopharyngeal carriage and the subsequent
transmission of vaccine serotypes [14–19] as well as disease caused
by vaccine serotypes [20,21] has been observed. Evidence has
been published on pneumococcal disease reduction in non-
vaccinated populations in the US [22], UK [8], Australia [23],
Netherlands [11], and other countries. Whereas herd protection
would generally be expected in populations with sufficient
paediatric vaccination uptake, it is in fact difficult to predict the
exact epidemiological effect of broad scale use of PCVs in new
settings [24], due to variation in the circulating serotypes and the
inherent differences among them, as well as programmatic
differences including the level of uptake and intensity of catch-
up programs. Furthermore, although overall invasive pneumococ-
cal disease (IPD) rates decreased after the introduction of PCV7,
there has simultaneously been an increase of cases due to non-
PCV7-vaccine serotypes. Many clinical studies have shown that, at
the level of the nasopharynx, the use of PCV7 is followed by a shift
from colonisation with vaccine types (VTs) to predominantly non-
vaccine types (NVTs) [25]. Recent research mitigates the notion
that serotype replacement would be of a scale potentially offsetting
the direct and herd protection effects of the PCV. In particular,
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Miller et al (2011) [8] claim that further reductions might be
achievable by use of higher-valent vaccines.
This being said, however, a great deal of uncertainty remains
regarding major drivers such as long-term replacement disease
and herd protection among unvaccinated individuals. Under-
standing the epidemiologic shifts following the introduction of
PCV7 is relevant for the introduction of the newer higher-valent
vaccines. Multiple factors affect serotype patterns. The vaccine
could be the cause of replacement, but antibiotic use and
resistance, as well as other biological characteristics of the
individual serotypes, which indeed present considerable variations,
may also influence serotype distributions. Previous epidemiological
and health-economic analyses of higher-valent PCVs exclusively
utilised static models [26]. However, currently it is well recognised
that to model the changes in pneumococcal epidemiology after
vaccination a dynamic model is required, which could take into
account all these indirect effects. Only recently, van Hoek et al
(2012) [27] evaluated the cost-effectiveness of the introduction of
PCV13 in England and Wales using a deterministic transmission
model to generate epidemiological projections of vaccine impacts.
The importance of using dynamic designs, as opposed to static
approaches, to explicitly model the spread of bacteria and viruses
has previously been illustrated [28–30]. The use of different
modelling approaches has shown huge differences when analysing
screening for Chlamydia trachomatis [28] and pertussis vaccination
strategies [29,30]. To fully capture the value of infant PCV
programs, it is necessary to develop a dynamic model that
incorporates such indirect effects. The development of such
models fits into the priority of designing innovations in health
technology assessments, but requires input from mathematical,
medical, epidemiological, and immunological fields, and scientific
applications of such rigorous undertakings are few.
Melegaro et al (2010) [31] were the first to develop an age-
structured transmission dynamic model that retrospectively
studied the impact of PCV7 on IPD considering serotype
replacement. A Susceptible-Infected-Susceptible (SIS) model was
developed that considered reinfection and co-infection with NVTs
and VTs. Carriage prevalence data and surveillance of IPD came
from England and Wales, while degree and duration of vaccine
protection and competition were derived using available US data.
This study found that PCV7 vaccination could eradicate VTs, but
increased the NVTs with the consequent possible increase of IPD.
The authors claimed, however, that their results were sensitive to
changes in protection effects and level of competition.
In the UK, a more rapid replacement of PCV7 IPD cases by
non-PCV7 IPD cases was observed compared with the US.
Consequently, in recent work by Choi et al (2011) [32], the model
of Melagaro et al (2010) [31] was re-parameterised using vaccine
coverage and IPD data from England and Wales, as well as
European Union social contact mixing patterns [33]. The authors
concluded that PCV7 vaccination could result in a decrease in
overall IPD, mostly in children, even with a rapid replacement by
NVTs within 5 years of vaccine introduction at high coverage.
They also found that stopping vaccination could result in a
resurgence of VT disease to pre-vaccination levels.
In the Netherlands, vaccination with PCV7 was introduced for
all infants born after March 31, 2006. The schedule of
vaccinations was 3 infant doses and 1 toddler dose (i.e. 3+1) at
ages 2, 3, 4, and 11 months, with no catch-up campaign. As of
2011, PCV10 replaced PCV7 in the infant pneumococcal
vaccination schedule. Rozenbaum et al (2010) [34] have found,
using a static model, that the Dutch infant vaccination program of
4 doses of PCV7 is no longer cost-effective because of increases in
IPD caused by NVTs. They claim that PCV13 could provide
better benefits because of an increase in herd immunity and less
replacement disease. The aim of this paper is to evaluate the
potential effectiveness of PCV13 on IPD in a Dutch infant
national immunisation program setting, using a dynamic model
that takes into account disease transmission dynamics.
Methods
The age-structured transmission dynamic model was adapted
from Melegaro et al (2010) [31], in order to evaluate the
effectiveness of PCV13 in the Netherlands. Similarly to Melegaro
et al (2010) [31], the model here is composed of two parts, a pre-
vaccination model and a transmission dynamic model, to explore
the effects of the vaccination program.
Part I: Pre-Vaccination Model
The forces of infection for VT and NVT were first estimated
from the pre-PCV carriage data (lVi, lNi), with i reflecting age
groups, V the VT, and N the NVT. The flowchart in Figure 1
represents the SIS structure used to consider pneumococcal
carriage. Briefly, the characteristics of the SIS model were:
N 4 compartments: S = susceptible; V= VT carriers; N= NVT
carriers; and B= both VT and NVT co-colonised
N Age-dependent forces of infection for VT and NVT (lVi, lNi)
N Competition parameters that determined the relative risk of
acquiring VT (NVT) if already colonised by NVT (VT) (cV,
cN)
N Recovery rates for VT and NVT
The forces of infection were assumed as step functions, with a
constant value in each of the following age groups: 0–1, 2–4, 5–9,
10–19, 20–29, and $30 years. The recovery rate was assumed to
be equal to the inverse of the duration of carriage as in Cauchemez
et al (2006) [35] and Melegaro et al (2007) [36]. Competition
parameters were based on point estimates and lower and upper
Figure 1. Susceptible-Infected-Susceptible (SIS) model struc-
ture. SIS model structure for estimating the forces of infection for
vaccine types and non-vaccine types. Abbreviations: lN, age-dependent
forces of infection for non-vaccine types; lV, age-dependent forces of
infection for vaccine types; B, both vaccine types and non-vaccine types
co-colonised; cN, competition parameters that determined the relative
risk of acquiring non-vaccine types if already colonised by vaccine
types; cV, competition parameters that determined the relative risk of
acquiring vaccine types if already colonised by non-vaccine types; i, age
group; N, non-vaccine types carriers; rN, recovery rate for non-vaccine
types; rV, recovery rate for vaccine types; S, susceptible; V, vaccine type
carriers;.
doi:10.1371/journal.pone.0089415.g001
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bounds of confidence intervals derived in Melegaro et al (2007)
[36] and Choi et al (2011) [32]. In particular, cV was fixed at 0.5,
whereas cN took the value 0.04 [32]. Different values of cN (0 and
0.37) have been used and are reported in the sensitivity analysis, as
described below. A low value of cN indicates strong competition
between the VT and the NVT group, i.e. carriers of one type are
less likely to acquire the other type compared with susceptible
individuals. The recovery rates were assumed age-dependent but
equal among the two groups (rVi= rNi).
A multinomial model was used to fit force-of-infection
parameters to carriage data. The co-colonised individuals were
grouped within the VT compartment because they were assumed
to be detected as VT carriers. The multinomial model is as follows:
logL~
Xn
i~1,:::n
(VTi|logvtizNVTi|lognvtizSi|logsi)zconstant
where i = age group, VT= observed number of VT carriers, vt =
predicted prevalence of VT carriers, NVT= observed number of
NVT carriers, nvt = predicted prevalence of NVT carriers, S =
observed number of susceptibles, and s = predicted prevalence of
susceptibles.
The model was solved for the combination of parameter values
that produced the best fit.
Part II: Dynamic Model to Evaluate Vaccination Policies
The second part of the model consisted of a dynamic model for
S. pneumoniae, comprising a set of ordinary differential equations
(see Melegaro et al [2010] for details [31]). The flow chart in
Figure 2 shows the natural history of carriage with and without
vaccination. The crucial characteristics of the model are as follows:
N The model was age-structured with 100 cohorts of individuals
that age every year
N Each individual was born at age 0 and was susceptible
N The model comprised 4 compartments without vaccination:
S= susceptible; V= VT carriers; N= NVT carriers; and B=
both VT and NVT co-colonised
N The model comprised 4 compartments with vaccination: Sv=
susceptible; Vv= VT carriers; Nv= NVT carriers; and Bv=
both VT and NVT co-colonised
N Age-dependent forces of infection for VT and NVT (lVi, lNi)
N Competition parameters that determined the relative risk of
acquiring VT (NVT) if already colonised by NVT (VT) (cV,
cN)
N Recovery rates for VT and NVT were assumed to be equal
(rVi= rNi)
N Vaccination coverage was reflected by vi, the degree of
protection by ci, and the waning rate by vi
The model was parameterised as reported in Table 1 [32,35–
40], where the initial conditions were the pre-vaccination carriage
prevalences for VT and NVT as estimated in Part I. The mixing
parameter (e) was estimated by fitting the transmission dynamic
model to the age-specific IPD incidence rates pre- and post-PCV7
introduction, by minimising the Poisson deviance (data not
shown). We assumed that the pre-PCV13 vaccination years
corresponded with the pre-PCV7 vaccination years; therefore, we
used carriage data estimated by van Gils et al (2009) [38] and an
average of the IPD cases in the 2-years pre-PCV7 (June 2004–June
2006), taking the 13 serotypes included in PCV13 explicitly into
account.
Inputs
Vaccination program. The model considered routine vac-
cination with PCV13 of infants at 2, 3, 4, and 11 months of age
(3+1), without considering any catch-up campaign.
Carriage prevalence. Pre-vaccination nasopharyngeal car-
riage rates of S. pneumoniae were derived from a longitudinal,
randomised controlled trial implemented in the Netherlands from
July 2005 and February 2006 (ClinicalTrials.gov identifier:
NCT00189020). In this trial, 1003 healthy newborns and 1 of
their parents were enrolled to examine the effects of a 2-dose and
2+1 dose schedule with PCV7 [38]; serotype information data
were also reported in Spijkerman et al (2011) [39]. As data were
not available for all age groups, a quadratic function was used to
predict pre-vaccination carriage prevalence for missing age
groups.
The above data were also used, together with recent data from a
cross-sectional observational study by Spijkerman et al (2011) [39]
on pneumococcal carriage in the Netherlands 3-years post-PCV7,
to estimate the level of assortativeness in the mixing patterns.
Disease incidence. Infections that progressed into IPD were
estimated based on fitting a model to the age-specific incidence of
disease attributable to pneumococcal invasive infection as reported
by the Netherlands Reference Laboratory for Bacterial Meningitis
from 2004–2010, assuming a constant case-carrier ratio over time
[40].
Population data. Model outcomes on IPD-cases were
extrapolated to national totals using Dutch demographic data
for the year 2006 from the Dutch Central Bureau of Statistics
(Voorburg, Netherlands).
Sensitivity Analysis
Sensitivity analyses were conducted around the competition and
mixing parameters. Specifically, we tested scenarios where cN was
equal to 0 or 0.37, representing lower and higher competition,
respectively [32]. A higher cN implies a lower replacement of VT
by NVT after the introduction of the vaccine. In the base-case the
mixing parameter (e) was estimated at 0.85 using PCV7 data.
Subsequently we tested values of e at 0.50 or 1.00, representing
different levels of assortativeness in the mixing patterns (when
e=1.00, mixing is totally assortative). When a more proportionate
mixing pattern (e=0.50) was considered, it simulated a situation
where additional indirect effects among unvaccinated age groups
might occur.
Results
The pre-vaccination model resulted in a good fit to the data
with the exception of ages 0 and 1 years. Figure 3 compares
observed versus estimated steady-state carriage pre-PCV13 where
cN=0.04.
The base-case pre-vaccination, and 10 and 40 years post-
PCV13 introduction IPD incidence per 100,000 population for
VT, NVT, and overall IPD incidences (VT+NVT diseases) are
presented in Figure 4. The model predicted a rapid decrease of
the VT and overall incidence for the age-groups 0–1 years, and
also a relevant decrease of the VT and overall incidence for the $
65 years age groups.
Figure 5 presents VT, NVT, and overall IPD incidence per
100,000 population, over time with e fixed at 0.85, while varying
the competition parameter cN=0, 0.04, and 0.37. Figures 5A and
5B show that the model was sensitive to cN; a higher cN implies a
Transmission Dynamic Model of PCV13 Impact
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lower replacement of VT by NVT after the introduction of the
vaccine; therefore, the VT incidences are higher and the NVT
incidences are lower compared with a lower cN in all age groups.
In Figure 5C, the overall incidence is about the same for all three
parameters. However, some effects of the different values of cN
were apparent once we stratified by VT or NVT incidences. Here,
when cN=0.37, the overall IPD incidence decreased in the age
groups 0–1 and 45–64 years, was constant in age groups 2–44
years, and increased for people aged $65 years. This is because
there was a combination of two opposing effects: increase of VT
incidence and decrease of NVT incidence. The model predicted
an overall decrease in IPD incidence in the 0–1 years age group.
Specifically, the overall IPD incidences (per 100,000 population)
20 years after the introduction of PCV13 in the 0–1 years age
group were 118.65 if cN=0, 118.00 if cN=0.04, and 105.43 if
cN=0.37. However, the overall IPD incidences (per 100,000
population) 20 years after the introduction of the vaccine in the $
75 years age group were 491.94 if cN=0, 492.44 if cN=0.04, and
498.22 if cN=0.37.
Figure 6 presents VT, NVT, and overall IPD incidence per
100,000 population, over time with cN fixed at 0.04, while varying
the mixing parameter e=0.50, 0.85, and 1.00. As higher values of
e imply less mixing, IPD incidence, therefore, had a larger
decrease over time when the mixing was more proportionate
Figure 2. Dynamic transmission model. Flowchart representing the dynamic mathematical model used for the transmission. Abbreviations:ci,
degree of protection; lN, age-dependent forces of infection for non-vaccine types; lV, age-dependent forces of infection for vaccine types; vi, the
waning rate; B, both vaccine types and non-vaccine types co-colonised; Bv, both vaccine types and non-vaccine types co-colonised with vaccination;
cN, competition parameters that determined the relative risk of acquiring non-vaccine types if already colonised by vaccine types; cV, competition
parameters that determined the relative risk of acquiring vaccine types if already colonised by non-vaccine types; i, age group; N, non-vaccine types
carriers; Nv, non-vaccine types carriers with vaccination; rN, recovery rate for non-vaccine types; rV, recovery rate for vaccine types; S, susceptible; Sv,
susceptible with vaccination; v, vaccination coverage; V, vaccine type carriers; Vv, vaccine types carriers with vaccination.
doi:10.1371/journal.pone.0089415.g002
Table 1. Model parameters and ranges for the analysis of PCV13 in the Netherlands.
Parameters Definition Values Ranges in sensitivity analysis Sources [Ref.]
u Coverage 95% RIVM [37]
cN Competition VT 0.04 0–0.37 Choi et al (2011) [32]
cV Competition NVT 0.50 Melegaro et al (2007) [36]
e Assortativeness 0.85 0.50–1.00 Estimated using pre- and post-PCV7 data [38,39]
c Degree of protection 0.52a Choi et al (2012) [40]
d Duration of protection 5 years Choi et al (2012) [40]
rvi Recovery rate for VT 1/duration carriage Cauchemez et al (2006) [35] Melegaro et al (2007) [36]
rni Recovery rate for NVT 1/duration carriage Cauchemez et al (2006) [35] Melegaro et al (2007) [36]
aWe used the same degree of protection for PCV13 that was estimated by Choi et al (2011) [32] for PCV7. Sensitivity analysis was done on this value.
Abbreviations: NVT, non-vaccine types; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; RIVM, National Institute for
Public Health and the Environment, Ministry of Health, Welfare and Sport; VT, vaccine types.
doi:10.1371/journal.pone.0089415.t001
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(e=0.50) leading to a higher herd protective effect. The opposite
happened when mixing was fully assortative (e=1.00), and
incidence remained nearly unchanged for older unvaccinated
age groups.
Discussion
Using available Dutch data and a transmission dynamic model,
we estimated that 10 years after the introduction of PCV13, the
number of IPD cases per year (both VT and NVT) for children ,
2 years of age would be 45, reduced from 160 cases per year if no
vaccination had ever been implemented. At 10 years the
equilibrium was not fully reached yet; hence, after 30–40 years,
the IPD cases per year for children ,2 years of age reached 44.
For the elderly $75 years of age, IPD cases per year fell from 652
to 573 at equilibrium around 30 years after PCV13 introduction.
Overall, IPD cases per year in the Netherlands were predicted to
decrease from 2623 cases per year pre-vaccination to 2475, 2289,
2185, 2179, and 2178 cases per year at 5, 10, 20, 30, and 40 years
post-vaccination. Therefore, vaccination with PCV13 in the
Netherlands was predicted to lower IPD cases annually by up to
445 cases per year in the medium- to long-term.
Rozenbaum et al (2010) [41] recently estimated the cost-
effectiveness of PCV13 compared with no vaccination using a
static model that included herd protection and serotype replace-
ment in a straightforward linear relationship (termed ‘‘net indirect
effects’’). Using a total vaccination cost of approximately J300 for
4 doses, they estimated cost-effectiveness at approximately
J50,000 per quality-adjusted life year, based on a similar
reduction in IPD-cases in children aged #5 years, as found in
this study. However, the linear ‘‘net indirect effects’’ calculus
indicated a further reduction of only 181 cases; i.e. a total
reduction of 331 cases per year. This is in contrast to our current
analysis based on herd protection and serotype replacement within
a population dynamic design. Notably, here we estimated a
reduction in IPD cases already beyond this number after 10 years,
increasing to a reduction of approximately 440 cases per year 20–
40 years post-vaccination. Although we acknowledge that our
comparison was hampered by the different designs of both models,
we do note that both were built on the same dataset for IPD cases.
Therefore, a suggestion of the change in cost-effectiveness might
have some validity. Inserting the outcomes of the dynamic model
developed here into the cost-effectiveness model of Rozenbaum et
al (2010) [41] would improve the cost-effectiveness profile of
PCV13. Note that this estimate only concerns the reduction in
IPD cases; thus, potential further benefits in otitis media and
pneumonia might further improve cost-effectiveness.
Our results were quite robust for the sensitivity analyses that we
performed on the parameters that regulate herd immunity (e) and
competition (cN). Using PCV7 data, e was estimated at 0.85, which
is quite high, considering that 1.00 reflects full assortativeness.
Variation over the range 0.50–1.00 did not influence results
dramatically. However, a slight trend could be seen where lower
values of e (more proportionate mixing pattern) facilitated
elimination of VT-transmission with correspondingly higher
reductions in IPD cases. Furthermore, increasing the value of
the competition parameter cN — reflecting lower protection from
VT carriage — generally resulted in lower replacement of VT by
NVT after introduction of vaccination, and thus resulted in fewer
IPD cases, whereas a lower cN showed the opposite effect.
However, for the older age groups, the trend may reverse and thus
stabilise the overall number of IPD cases, explaining why the
results are relatively insensitive to the competition parameter.
As with all models, our model is limited by being a simplification
of reality and thus the above considerations should be taken with
caution. Our current model consisted of simplified population
structures and dynamics involving 100 cohorts of individuals (0, 1,
2, 3…99) each corresponding to one year of age and each of equal
size, with a total stable population (i.e. births equal deaths). An
additional crucial point of the current work relies on model
parameter estimates which, due to the lack of data from the
Netherlands, had to be extrapolated from other countries. In
particular, the competition parameter between VT and NVT
serotypes was based on estimates derived for England and Wales,
where post-PCV7 data were available for several years [32].
Vaccine efficacy against VT colonisation and duration of
protection were also taken from a study in England and Wales,
and were 52% and 5 years, respectively [40]. Although this is
clearly limiting the validity of our results, to our knowledge, these
represent the best sources of information concerning competition
between serotypes, as well as efficacy parameters being derived
using pre- and post-vaccination IPD data from the England and
Wales surveillance system. Finally, no natural immunity was
included in the model because the generation of naturally-
acquired immunity to pneumococcal serotypes is too complex and
poorly understood to be incorporated in the present model
structure. Clearly, all these assumptions can be updated when
additional data become available. This also applies to any desired
transitions from lower-valent vaccines to PCV13 as suggested by
our and potentially other analyses. For example, there are no data
yet on the transition in the first year of life from PCV7 to PCV13.
Long-term surveillance of IPD, carriage, and non-bacteraemic
pneumonia are crucial to understand vaccine effects over the long
term.
Another limitation is that this model only captures invasive
disease. Efficacy and effectiveness studies of PCV7 and PCV13
have shown a substantial impact on non-invasive disease as well.
These disease states are not included in our analysis because
Figure 3. Carriage pre-PCV13. Estimated and observed carriage pre-
PCV13. Prevalence rates are reported per each age or age group. Note
that only the data points in Figure 3 at ages 1 and 2 years, and age
group 30–39 years correspond to observed carriage data; other points
were interpolated. Abbreviations: cN, competition parameter; NVT, non-
vaccine types; PCV13, 13-valent pneumococcal conjugate vaccine; VT,
vaccine types.
doi:10.1371/journal.pone.0089415.g003
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serotype-specific data on pneumonia and acute otitis media are too
scarce to attempt to predict long-term effects of vaccine pressures
on VT and NVT. Again, further surveillance studies on non-IPD
will be crucial in evaluating the further impact the vaccine will
have on these conditions.
Currently in the Netherlands PCV10 is used having replaced
PCV7 in 2011. To date, the impact of PCV10 on carriage remains
uncertain [42–45], and a herd effect has not yet been demon-
strated. For this reason PCV10 was not included in the
transmission dynamic analysis. If and when such data become
available, the analysis can be updated to include the effects of
PCV10.
Miller et al (2011) [46] have shown that the incidence of IPD
caused by PCV13-only serotypes halved in children aged ,2 years
in England and Wales where PCV13 replaced PCV7 in 2010.
This is due to protection against serotypes 7F and 19A in
particular, which were the main causes of replacement disease.
However, Miller et al (2011) [46] claimed that it was too early to
see indirect effects in older ages or serotype replacement effects in
the vaccinated population. However, in the US, indirect effects
have been observed with no evidence yet of serotype replacement
in all adult age groups within 1.5 years of implementation of the
PCV13 National Immunisation Programme [47,48].
In conclusion, we have adapted to the Netherlands setting the
first application of transmission dynamic modelling for the spread
of pneumococci and potential subsequent IPD. We estimated a
base-case reduction in IPD due to PCV13 vaccination of up to 445
cases per year, including herd protective and serotype replacement
indirect effects. When compared with the previously-published
static model [41], which included a linear approximation of
indirect effects, we estimated slightly higher reductions in IPD in
the Netherlands due to these indirect effects, potentially translating
to more favourable cost-effectiveness of PCV13 than previously
indicated. Sensitivity analyses showed that results are sensitive to
the competition parameter arranging the exchange between VT
and NVT, and the type of population mixing. This work is the first
attempt to quantify the overall effects of a PCV13 programme in
the Dutch population taking into account all the direct and
indirect effects on IPD. However, further research is clearly
needed in order to evaluate the potential overall effects on non-
IPD, which represent a major widespread burden in terms of both
morbidity and cost.
Figure 4. Yearly incidence of IPD. IPD yearly incidence per 100,000 population pre-vaccination (0 years) and after 10 and 40 years post-PCV13
with the competition parameter cN=0.04. Abbreviations: cN, competition parameter; IPD, invasive pneumococcal disease; NVT, non-vaccine types;
PCV13, 13-valent pneumococcal conjugate vaccine; VT, vaccine types.
doi:10.1371/journal.pone.0089415.g004
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Figure 5. Yearly incidence of IPD with different competition parameters. A, IPD incidence, VT; B, IPD incidence, NVT; and C, IPD overall
incidence. Yearly incidence per 100,000 population over time when different competition parameters are used: cN=0, 0.04, and 0.37; and the mixing
parameter is e= 0.85. Each panel corresponds to a different age group. Note: the y-axis scales are different on each graph. Abbreviations: cN,
competition parameter; e, mixing parameter; IPD, invasive pneumococcal disease; NVT, non-vaccine types; VT, vaccine types.
doi:10.1371/journal.pone.0089415.g005
Figure 6. Yearly incidence of IPD with different mixing parameters. A, IPD incidence, VT; B, IPD incidence, NVT; and C, IPD overall incidence.
Yearly incidence per 100,000 population over time when different mixing parameters are used: e= 0.50, 0.85, 1.00; and the competition parameter is
cN=0.04. Each panel corresponds to a different age group. Note: the y-axis scales are different on each graph. Abbreviations: cN, competition
parameter; e, mixing paremeter; IPD, invasive pneumococcal disease; NVT, non-vaccine types; VT, vaccine types.
doi:10.1371/journal.pone.0089415.g006
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